These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31597437)

  • 41. Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease.
    Liu YY; Zhang WY; Zeng DX
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1139. PubMed ID: 31657472
    [No Abstract]   [Full Text] [Related]  

  • 42. Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease?
    Dai C; Jiang M
    Am J Gastroenterol; 2020 Feb; 115(2):303-304. PubMed ID: 31809300
    [No Abstract]   [Full Text] [Related]  

  • 43. Nonalcoholic fatty liver disease and statins.
    Tziomalos K; Athyros VG; Paschos P; Karagiannis A
    Metabolism; 2015 Oct; 64(10):1215-23. PubMed ID: 26234727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?
    Athyros VG; Katsiki N; Mikhailidis DP
    Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G681-G682. PubMed ID: 28596414
    [No Abstract]   [Full Text] [Related]  

  • 45. Letter to the Editor: Chronic Hepatitis B and Nonalcoholic Steatohepatitis: Is "Fat" All Bad?
    Li J; Cheung RC; Nguyen MH
    Hepatology; 2020 Feb; 71(2):768. PubMed ID: 31595532
    [No Abstract]   [Full Text] [Related]  

  • 46. Homocysteine in nonalcoholic steatohepatitis: A reply.
    Polyzos SA; Kountouras J
    Eur J Intern Med; 2016 Nov; 35():e40-e41. PubMed ID: 27423982
    [No Abstract]   [Full Text] [Related]  

  • 47. Nonalcoholic Fatty Liver Disease and Liver Transplantation.
    Pham T; Dick TB; Charlton MR
    Clin Liver Dis; 2016 May; 20(2):403-17. PubMed ID: 27063277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Important issues for selecting patients with nonalcoholic fatty liver disease: a biochemical view.
    Sertoglu E; Kayadibi H; Uyanik M
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):937. PubMed ID: 24987826
    [No Abstract]   [Full Text] [Related]  

  • 49. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?
    Kahali B; Liu YL; Daly AK; Day CP; Anstee QM; Speliotes EK
    Gastroenterology; 2015 Apr; 148(4):679-84. PubMed ID: 25639710
    [No Abstract]   [Full Text] [Related]  

  • 51. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease - authors' reply.
    Mullish BH; Forlano R; Abeles RD; Thursz MR; Manousou P
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1093-1094. PubMed ID: 30920045
    [No Abstract]   [Full Text] [Related]  

  • 52. Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
    Huang JF; Dai CY; Yu ML; Chuang WL
    Hepatology; 2020 Aug; 72(2):781. PubMed ID: 31970797
    [No Abstract]   [Full Text] [Related]  

  • 53. Cardiovascular risk estimation in non alcoholic fatty liver disease.
    Romdhane H; Cheikh M; Ennaifer R; Mahmoud Y; Bougassas W; Ben Nejma H; Bel Hadj N
    Tunis Med; 2016 Dec; 94(12):839. PubMed ID: 28994882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic fatty liver disease-related cardiovascular risk: Is there an association with blood hemoglobin levels?
    Tanoglu A; Kara M
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1126-9. PubMed ID: 26193051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Nonalcoholic fatty liver disease in the elderly].
    Wang B; Liu L
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):92-5. PubMed ID: 26983474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis.
    Pacana T; Fuchs M
    Clin Liver Dis; 2012 Aug; 16(3):599-613. PubMed ID: 22824483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk.
    Ahmed MH; Husain NE; Malik A; Woodward C; Mital D
    AIDS Rev; 2017; 19(4):190-197. PubMed ID: 29271970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction.
    Federico A; Dallio M; Masarone M; Persico M; Loguercio C
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4731-4741. PubMed ID: 27906428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.
    Mantovani A; Ballestri S; Lonardo A; Targher G
    Dig Dis Sci; 2016 May; 61(5):1246-67. PubMed ID: 26809873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The assessment of cardiovascular risk factors in patients with nonalcoholic fatty liver disease].
    Chubirko KI; Ivachevs'ka VV; Hechko MM; Chopeĭ IV; Stan MP; Koshelia II
    Wiad Lek; 2014; 67(2 Pt 2):332-4. PubMed ID: 25796862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.